Flumatinib, or flumatinib mesylate tablets, is a second-generation tyrosine kinase inhibitor drug used for chronic myeloid leukemia, and needs to be used in accordance with medical advice.
Flumatinib mesylate tablets is a tyrosine kinase inhibitor, a second-generation drug. It mainly inhibits the proliferation of leukemia tumor cells and induces apoptosis of tumor cells by inhibiting Bcr-Abl tyrosine kinase activity. It is used for the treatment of adult (Philadelphia chromosome-positive) chronic myeloid leukemia in chronic stage.
Adverse reactions of Flumatinib Mesylate Tablets can be seen in thrombocytopenia, leukopenia, neutropenia, anemia, lymphopenia and other bone marrow transplantation, diarrhea, abdominal pain, vomiting, nausea, abdominal discomfort, toothache, hepatic impairment, upper respiratory tract infections, lung infections, urinary tract infections and other adverse reactions.
The drug is contraindicated for those who are allergic to the components of the product. The medication should be used under the supervision of a doctor to avoid any misunderstanding.